文献速递膀胱癌与上尿路尿路上皮癌

阿替利珠单抗新辅助治疗不适合顺铂的肌层浸润性膀胱尿路上皮癌患者的最终结果

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
PubMed 文献 · Eur Urol · 2022-05-14

ABACUS 是一项多中心、单臂、新辅助、2 期试验,纳入不适合或拒绝顺铂新辅助化疗的肌层浸润性膀胱癌(T2-4aN0M0)患者,术前给予两个周期阿替利珠单抗。中位随访 25 个月,病理完全缓解率为 31%(27/88,95%CI 21-41),2 年无病生存率和总生存率分别为 68%(95%CI 58-76)和 77%(95%CI 68-85)。基线基质 CD8+ 高表达与无复发生发相关(HR 0.25,95%CI 0.09-0.68,p=0.007),循环肿瘤 DNA 状态在各时间点均有高度预后价值。

要点

  • 不适合顺铂的患者接受两周期阿替利珠单抗新辅助治疗后,病理完全缓解率为 31%(27/88)。
  • 2 年无病生存率和总生存率分别为 68% 和 77%,达到病理完全缓解者 2 年无病生存率为 85%。
  • 基线基质 CD8+ 高表达与无复发生存相关(HR 0.25),循环肿瘤 DNA 阳性状态在各时间点均有高度预后价值。

核心结论

  • 肌层浸润性膀胱癌新辅助阿替利珠单抗与临床反应和高无病生存率相关。
  • CD8+ 表达和连续循环肿瘤 DNA 水平与结局相关,可能有助于未来的个体化治疗。

研究设计与样本

  • ABACUS 为多中心、单臂、新辅助、2 期试验,纳入肌层浸润性膀胱癌(T2-4aN0M0)且不适合或拒绝顺铂新辅助化疗的患者。
  • 干预为根治性膀胱切除术前给予两个周期阿替利珠单抗,并收集连续组织和血液样本。
  • 主要终点为病理完全缓解率和 T 细胞生物标志物动态变化(已发表),次要结局为 2 年无病生存率和总生存率。
  • 95 例患者接受了至少一个周期阿替利珠单抗,8 例未行膀胱切除术(仅 1 例因疾病进展)。

主要发现

  • 中位随访时间为 25 个月(95%CI 25-26)。
  • 病理完全缓解率为 31%(27/88,95%CI 21-41)。
  • 2 年无病生存率为 68%(95%CI 58-76),2 年总生存率为 77%(95%CI 68-85)。
  • 达到病理完全缓解的患者 2 年无病生存率为 85%(95%CI 65-94)。
  • 基线 PD-L1 与无复发生存不相关(HR 0.60,95%CI 0.24-1.5,p=0.26),肿瘤突变负荷与无复发生存不相关(HR 0.72,95%CI 0.31-1.7,p=0.46)。

临床怎么用

  • 作者认为,肌层浸润性膀胱癌新辅助阿替利珠单抗与临床反应和高无病生存率相关。
  • 作者认为,CD8+ 表达和连续循环肿瘤 DNA 水平与结局相关,可能有助于未来的个体化治疗。

局限性

  • 缺乏随机化。
  • 生物标志物分析具有探索性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant immunotherapies hold promise in muscle-invasive bladder cancer (MIBC). OBJECTIVE: To report on 2-yr disease-free (DFS) and overall (OS) survival including novel tissue-based biomarkers and circulating tumor DNA (ctDNA) in the ABACUS trial. DESIGN, SETTING, AND PARTICIPANTS: ABACUS was a multicenter, single-arm, neoadjuvant, phase 2 trial, including patients with MIBC (T2-4aN0M0) who were ineligible for or refused neoadjuvant cisplatin-based chemotherapy. INTERVENTION: Two cycles of atezolizumab were given prior to radical cystectomy. Serial tissue and blood samples were collected. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoints of pathological complete response (pCR) rate and dynamic changes to T-cell biomarkers were published previously. Secondary outcomes were 2-yr DFS and OS. A biomarker analysis correlated with relapse-free survival (RFS) was performed, which includes FOXP3, major histocompatibility complex class I, CD8/CD39, and sequential ctDNA measurements. RESULTS AND LIMITATIONS: The median follow-up time was 25 mo (95% confidence interval [CI] 25-26). Ninety-five patients received at least one cycle of atezolizumab. Eight patients did not undergo cystectomy (only one due to disease progression). The pCR rate was 31% (27/88; 95% CI 21-41). Two-year DFS and OS were 68% (95% CI 58-76) and 77% (95% CI 68-85), respectively. Two-year DFS in patients achieving a pCR was 85% (95% CI 65-94). Baseline PD-L1 and tumor mutational burden did not correlate with RFS (hazard ratio [HR] 0.60 [95% CI 0.24-1.5], p = 0.26, and 0.72 [95% CI 0.31-1.7], p = 0.46, respectively). RFS correlated with high baseline stromal CD8+ (HR 0.25 [95% CI 0.09-0.68], p = 0.007) and high post-treatment fibroblast activation protein (HR 4.1 [95% CI 1.3-13], p = 0.01). Circulating tumor DNA positivity values at baseline, after neoadjuvant therapy, and after surgery were 63% (25/40), 47% (14/30), and 14% (five/36), respectively. The ctDNA status was highly prognostic at all time points. No relapses were observed in ctDNA-negative patients at baseline and after neoadjuvant therapy. The lack of randomization and exploratory nature of the biomarker analysis are limitations of this work. CONCLUSIONS: Neoadjuvant atezolizumab in MIBC is associated with clinical responses and high DFS. CD8+ expression and serial ctDNA levels correlated with outcomes, and may contribute to personalized therapy in the future. PATIENT SUMMARY: We showed that bladder cancer patients receiving immunotherapy followed by cystectomy have good long-term outcomes. Furthermore, we found that certain biological features can predict patients who might have particular benefit from this therapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Szabados B, Kockx M, Assaf ZJ, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol. 2022. PMID: 35577646. doi:10.1016/j.eururo.2022.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。